What is the price target for PROK stock?
15 analysts have analysed PROK and the average price target is 6.63 USD. This implies a price increase of 214.22% is expected in the next year compared to the current price of 2.11.
NASDAQ:PROK • US74291D1046
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PROKIDNEY CORP (PROK).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-16 | HC Wainwright & Co. | Initiate | Buy |
| 2025-07-15 | UBS | Maintains | Buy -> Buy |
| 2025-07-14 | Guggenheim | Maintains | Buy -> Buy |
| 2025-07-09 | Citigroup | Maintains | Buy -> Buy |
| 2025-06-30 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2024-09-30 | JP Morgan | Initiate | Neutral |
| 2024-09-10 | Guggenheim | Initiate | Buy |
| 2024-09-04 | B of A Securities | Maintains | Neutral -> Neutral |
| 2024-06-10 | Jefferies | Maintains | Buy -> Buy |
| 2024-05-29 | B of A Securities | Maintains | Neutral -> Neutral |
| 2024-01-02 | B of A Securities | Downgrade | Buy -> Neutral |
| 2023-07-25 | BTIG | Initiate | Buy |
| 2022-12-21 | Jefferies | Initiate | Buy |
| 2022-11-10 | Morgan Stanley | Initiate | Equal-Weight |
| 2022-10-18 | UBS | Initiate | Buy |
| 2022-10-14 | Citigroup | Initiate | Buy |
| 2022-09-02 | Evercore ISI Group | Initiate | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 76K | 893K 1,075.00% | 309.743K -65.31% | 291.72K -5.82% | 28.721M 9,745.40% | 159.38M 454.92% | 343.89M 115.77% | 1.263B 267.27% | 1.588B 25.73% | 1.917B 20.72% | ||
| EBITDA YoY % growth | -147.669M 1.53% | -172.92M -17.10% | -158.432M 8.38% | -177.7M -12.16% | -188.834M -6.27% | -165.044M 12.60% | -176.868M -7.16% | -55.59M 68.57% | N/A | N/A | N/A | |
| EBIT YoY % growth | -151.522M 0.97% | -178.352M -17.71% | -165.007M 7.48% | -172.011M -4.24% | -185.231M -7.69% | -82.824M 55.29% | -121.176M -46.31% | -10.761M 91.12% | 268.87M 2,598.56% | 397.39M 47.80% | 527.34M 32.70% | |
| Operating Margin | N/A | -234,673.68% | -18,477.83% | -55,533.53% | -63,496.09% | -288.37% | -76.03% | -3.13% | 21.29% | 25.02% | 27.51% | |
| EPS YoY % growth | -0.57 51.54% | -0.63 -10.53% | -0.52 17.46% | -0.59 -13.77% | -0.71 -19.58% | -0.40 44.06% | -0.34 14.95% | 0.20 160.61% | 0.15 -25.00% | 0.41 166.67% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.14 -8.28% | -0.15 -11.89% | -0.16 -30.05% | -0.17 -18.61% | -0.15 -8.70% | -0.11 22.86% | -0.11 28.10% | -0.11 32.43% |
| Revenue Q2Q % growth | 146.543K -36.29% | 146.543K -33.69% | 146.543K -32.47% | 180.54K -19.76% | 204K 39.21% | 204K 39.21% | 204K 39.21% | 204K 12.99% |
| EBITDA Q2Q % growth | -43.13M -8.40% | -44.881M -22.48% | -48.036M -42.11% | -49.639M -27.95% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -47.705M -15.26% | -49.676M -25.10% | -50.928M -32.15% | -54.319M -19.72% | -49.776M -4.34% | -47.022M 5.34% | -45.39M 10.87% | -47.532M 12.50% |
All data in USD
15 analysts have analysed PROK and the average price target is 6.63 USD. This implies a price increase of 214.22% is expected in the next year compared to the current price of 2.11.
PROKIDNEY CORP (PROK) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of PROKIDNEY CORP (PROK) is -0.14 USD and the consensus revenue estimate is 146.54K USD.
The consensus rating for PROKIDNEY CORP (PROK) is 78.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.